Efficacy and Tolerability of Intravenous Paricalcitol in Calcitriol-Resistant Hemodialysis Patients with Secondary Hyperparathyroidism: 12-Month Prospective Study

Figures & data

Figure 1. Flow diagram of study design.

Figure 2. Mean serum iPTH levels during the study period.

Figure 3. Monthly values of mean serum phosphorus and calcium during the study period.

Table 1. Basic demographic and laboratory characteristics of the study cohort.

Parameter	Value [mean ± SD (range)]
Number of patients (n)	40 (22 males, 18 females)
Mean age (years)	53 ± 17 (18–83)
Dialysis vintage (months)	72 ± 52 (18–276)
Hemoglobin (g/L)	11.6 ± 1.9
Albumin (g/dL)	4.1 ± 0.4
iPTH (pg/mL)	747 ± 497 (305–2454)
Calcium (mg/dL)	8.9 ± 0.8
Phosphorus (mg/dL)	4.6 ± 1.1
Ca × P	41.4 ± 11.6
Use of oral phosphate binder [n (%)]	40 (100)
Calcium containing [n (%)]	26 (65)
Sevelamer [n (%)]	8 (20)
Sevelamer + calcium containing [n (%)]	6 (15)

Note: iPTH, intact parathyroid hormone; SD, standard deviation.

Table 2. Comparison of pre- and posttreatment values in serum calcium, phosphorus, and iPTH levels and Ca × P.

Parameter	Pretreatment	12th month	p-Value
iPTH (pg/mL)	747.9 (465–861)	307.3 (81–392)	<0.001^a
Calcium (mg/dL)	8.9 ± 0.8	9.4 ± 0.7	0.07^b
Phosphorus (mg/dL)	4.6 ± 1.1	4.5 ± 0.9	0.713^b
Ca × P	41.4 ± 11.6	42.8 ± 10.3	0.473^b

Notes: iPTH, intact parathyroid hormone; SD, standard deviation.

^aWilcoxon signed-rank test, median (interquartile range).

^bPaired samples t-test, mean ± SD.

Figure 4. Percentage of patients according to iPTH values defined by KDOQI guidelines at 3-month intervals during the study course.